Abstract 116P
Background
Colorectal cancer (CRC) ranks as the second leading cause of mortality, following lung cancer, among cancer-related fatalities in High Income Asia Pacific (HIAP) nations. Despite this, there remains a lack of consistent and comparable data on the burden of CRC in these regions.
Methods
Utilizing tools from the Global Burden of Disease study, we examined CRC's prevalence, incidence, mortality, and disability-adjusted life years (DALYs) by age groups, sex, and years across four HIAP countries from 1990-2019. Moreover, we employed a regression framework model to project CRC-related deaths until 2040.
Results
The aggregate number of prevalent CRC cases surged from 450,169 (95%UI: 433,127-466,354) in 1990 to 1,178,847 (1,026,274-1,347,590) in 2019. During the same period, the death toll increased from 34,338 (32,598-35,179) to 76,929 (64,820-83,603). When considering the annual percentage change (APC), DALYs exhibited a 65% increase from 1990 to 2019. Notably, the age-standardized incidence rate (ASIR) demonstrated a 15% rise in APC, with the most pronounced increases occurring in South Korea (119%), Brunei Darussalam (21%), and Japan (13%). Conversely, Singapore exhibited a 7% decline in ASIR during the same timeframe. In terms of age-standardized mortality rate (ASMR), South Korea reported the highest APC (17%), while Singapore and Japan witnessed declines of 40% and 15%, respectively. The most significant APC in DALYs was noted in Brunei Darussalam (178%), trailed by South Korea (176%), Japan (89%), and Singapore (50%). In 2019, the age group of 85-89 experienced the highest CRC-related deaths, whereas the 75-79 age group exhibited the highest incidence. Meanwhile, the 70-74 age group showed the highest DALYs. Over the past three decades, males carried a greater burden compared to females. By 2040, a projected increase of 73,633 (52,895-102,526) CRC-related deaths is anticipated.
Conclusions
In 2019, CRC contributed to 13.88% of all cancer-related casualties in HIAP nations. The burden of CRC varied persistently among these countries. Nonetheless, it is evident that there is an urgent requirement for the implementation of more effective strategies to mitigate the burden posed by CRC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
123P - Spatial molecular profiling identifies FGF20 upregulation on cancer-associated fibroblast and FGFR2-PI3K/Akt activation in tumor cells of sporadic early-onset colon cancer
Presenter: Dave Hoon
Session: Poster Display
Resources:
Abstract
124P - Characteristics, prognosis and therapeutic effects of non-V600 BRAF mutated colorectal cancer
Presenter: Lalida Arsa
Session: Poster Display
Resources:
Abstract
125P - Final results of APOLLON-11 and SOYUZ-APOLLON study: Multicentre prospective observational post-authorization study of bevacizumab biosimilar in patients with metastatic colorectal cancer in real-world practice
Presenter: Alexey Tryakin
Session: Poster Display
Resources:
Abstract
126P - From tumor height (TH) to tumor regression grade (TRG) in locally advanced rectal cancers (LARC) during total neadjuvant therapy (TNT): A retrospective analysis
Presenter: Valeria Pusceddu
Session: Poster Display
Resources:
Abstract
127P - A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness
Presenter: Takayuki Yoshino
Session: Poster Display
Resources:
Abstract
128TiP - A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract
140P - Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
Presenter: Hoo Hwoei Fen Soo
Session: Poster Display
Resources:
Abstract
141P - Early phase trials outcomes in refractory upper GI cancers: A 10-year analysis from the SCRI UK phase I unit
Presenter: Antonella Cammarota
Session: Poster Display
Resources:
Abstract
142P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract
143P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display
Resources:
Abstract